Skip to content

POPular GUILTY PILOT: Genotype-guided Clopidogrel monotherapy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518464-12-00
Enrollment
200
Registered
2024-10-15
Start date
2024-10-15
Completion date
Unknown
Last updated
2024-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Non-ST-segment Elevation Acute Coronary Syndrome

Brief summary

The primary ischemic endpoints at 6 months is the composite of all-cause mortality, myocardial infarction, definite or probable stent thrombosis, and ischemic stroke, The primary bleeding endpoint at 6 months is major or minor bleeding (BARC type 2, 3 or 5 bleeding)

Detailed description

Primary ischemic and bleeding endpoint at 1 month, Each individual component of the primary endpoints at 1 and 6 months, Cardiovascular mortality at 1 and 6 months., Non-cardiovascular mortality at 1 and 6 months., Any need for revascularization at 1 and 6 months., Any periprocedural complications.

Interventions

Sponsors

Sint Antonius Ziekenhuis Stichting
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary ischemic endpoints at 6 months is the composite of all-cause mortality, myocardial infarction, definite or probable stent thrombosis, and ischemic stroke, The primary bleeding endpoint at 6 months is major or minor bleeding (BARC type 2, 3 or 5 bleeding)

Secondary

MeasureTime frame
Primary ischemic and bleeding endpoint at 1 month, Each individual component of the primary endpoints at 1 and 6 months, Cardiovascular mortality at 1 and 6 months., Non-cardiovascular mortality at 1 and 6 months., Any need for revascularization at 1 and 6 months., Any periprocedural complications.

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026